结论：糖尿病肾病患者存在血浆纤溶酶原激活物及其抑制物系统失衡。
Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.
血浆纤溶酶原激活物抑制剂(PAI) - 1是纤溶系统的主要调控因子。
Plasminogen activator inhibitor-1 (PAI-1) is the main regulator of the fibrinolytic system.
对54例白血病患者进行血浆纤溶酶原(plg)及纤溶酶(PL)活性测定。
We measured the plasminogen (PLG) content and plasmin (pl) activity in 54 leukemic patients.
目的观察罗格列酮对2型糖尿病患者血脂水平和血浆纤溶酶原激活物抑制剂1 (PAI - 1)活性的影响。
Objective To investigate the influence of rosiglitazone on blood lipids and plasma PAI-1 activity in type 2 diabetic patients.
方法：检测33例糖尿病肾病患者及30例健康体检对照组血浆纤溶酶原激活物抑制物-1（PAI-1），观察检测结果。
Method Plasminogen activator inhibitor-1(PAI-1) in 33 cases of diabetic nephropathy and 30 healthy controls were detected, and the test results were observed.
目的：探讨急性冠脉综合征患者应用阿托伐他汀调脂治疗后对血管内皮舒张功能、血浆纤溶酶原激活物抑制物1及血管内皮素1的影响。
Objective To study the effects of atorvastatin cholesterol-lowering therapy on vascular endothelial function and plasminogen activator inhibitor-1 in acute coronary syndromes.
作者研究了血浆和组织激肽释放酶激活纤溶酶原的机制。
We studied the mechanism of plasma and tissue kallikrein in activating plasminogen.
用酶联免疫吸附法检测血浆血管性假性血友病因子、凝血酶调节蛋白、纤溶酶原激活物抑制物1水平。
The von Willebrand's disease factors in plasm, adjusted protein of thrombase and inhibitor 1 of activator of plasminogen were detected with enzyme-linked immunosorbent assay.
方法采集42例急性脑梗死患者血浆，测定其纤维蛋白原、d二聚体及纤溶酶原含量，并与对照组进行比较。
Methods Collecting the plasma of 42 acute cerebral infarction patients, the content of fibrinogen? D dimer and fibrinolysin was determined, and was compared with their content in control group.
目的探讨血浆组织型纤溶酶原激活物(t -PA)及其抑制物(PAI - 1)在急性脑梗死发病中的意义。
Objective To assess the clinical significance of plasma t-PA, PAI-1 in acute cerebral infarction.
纤溶酶原激活物抑制物1 (PAI - 1)是血浆纤维蛋白溶解系统的重要组成物之一，对维持血浆纤溶系统的稳定起重要作用。
Plasminogen activator inhibitor-1 (PAI-1) is one of the important components of the plasma fibrinolytic system and plays an key role in maintaining its stability.
应用较为先进的检测手段，对84例恶性肿瘤患者血浆激肽释放酶原（PK）、纤溶酶原（PLG）、纤维蛋白原（FIG）进行测定，共100例次。
Plasma levels of prekallikrein (PK), plasminogen (PLG), fibrinogen (FIG) in 84 cases of malignant tumor were studied with an advanced method. Each item was measured 100 times.
应用较为先进的检测手段，对84例恶性肿瘤患者血浆激肽释放酶原（PK）、纤溶酶原（PLG）、纤维蛋白原（FIG）进行测定，共100例次。
Plasma levels of prekallikrein (PK), plasminogen (PLG), fibrinogen (FIG) in 84 cases of malignant tumor were studied with an advanced method. Each item was measured 100 times.
应用推荐